Pharmacokinetics of temozolomide given three times a day in pediatric and adult patients

Cancer Chemotherapy and Pharmacology

Volumn 52, Issue 6, 2003, Pages 459-464

  Riccardi, Anna ^a   Mazzarella, Giorgio ^a   Cefalo, Graziella ^b   Garrè, Maria Luisa ^c   Massimino, Maura ^b   Barone, Carlo ^a   Sandri, Alessandro ^d   Ridola, Vita ^a   Ruggiero, Antonio ^a   Mastrangelo, Stefano ^a   Iazzareschi, Ilaria ^a   Caldarelli, Massimo ^e   Maira, Giulio ^e   Madon, Enrico ^d   Riccardi, Riccardo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c G GASLINI INSTITUTE   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

Author keywords

Brain tumors pharmacokinetics; Chemotherapy; Children; Temozolomide

Indexed keywords

TEMOZOLOMIDE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG HALF LIFE; FEMALE; HUMAN; MALE; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALF-LIFE; HUMANS; LINEAR MODELS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEUTROPENIA; THROMBOCYTOPENIA;

EID: 0345375541     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0677-x     Document Type: Article

References (22)

1. 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 5:309
2. Bleehen NM, Newlands ES, Lee SM, Thatcher LN, Selby P, Calvert AH, Rustin GJ, Brampton M, Stevens MF (1995) Cancer research campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 13:910
3. Bower M, Newlands ES, Lee SM, Thatcher LN, Selby P, Calvert AH, Rustin GJ, Brampton M, Stevens MF (1997) Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 40:484
4. Brada M, Judson I, Beale P, Moore S, Reidenberg P, Statkevich P, Dugan M, Batra V, Cutler D (1999) Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 81:1022
5. Britten CD, Rowinsky EK, Baker SD, Agarwala SS, Eckardt JR, Barrington R, Diab SG, Hammond LA, Johnson T, Villalona-Calero M, Fraass U, Statkevich P, Von Hoff DD, Eckhardt SG (1999) A phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. Clin Cancer Res 5:1629
6. Brock CS, Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I, Roddie M, Glaser M, Brampton MH, Rustin GJ (1998) Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 58:4363
7. Dhodapkar M, Rubin J, Reid JM, Burch PA, Pitot HC, Buckner JC, Ames MM, Summan V (1997) Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res 3:1093
8. Estlin EJ, Lashford L, Ablett S, Price L, Gowing R, Gholkar A, Kohler J, Lewis IJ, Morland B, Pinkerton CR, Stevens MCG, Mott M, Stevens R, Newell DR, Walker D, Dicks-Mireaux C, McDowell H, Reidenberg P, Statkevich P, Marco A, Batra V, Dugan M, Pearson ADJ (1998) Phase I study of temozolomide in pediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group. Br J Cancer 78:652
9. Friedman HS, Kerby T, Calvert H (2000) Temozolomide and treatment of malignant glioma. Clin Cancer Res 6:2585
10. Gibson NW, Hickman JA, Erickson LC (1985) DNA cross-linking and cytotoxicity in normal and transformed human cells treated in vitro with 8-carbamoyl-3-(2-chloroethyl) imidazo[5,1-d]1,2,3,5-tetrazin-4(3H)-one. Cancer Res 44:1772
11. Hammond LA, Eckardt JR, Baker SD, Eckardt SG, Dugan M, Forral K, Reidenberg P, Statkevich P, Weiss GR, Rinaldi DA, Von Hoff DD, Rowinsky EK (1999) Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol 17:2604
12. 6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br J Cancer 69:452
13. Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS, Quarterman CP, Hoffman R, Stevens MFG, Brampton MH, Gibson AC (1992) Phase I trial of temozolomide (CCRG 81045:M&B39831: NSC362856). Br J Cancer 65:287
14. Nicholson HS, Krailo M, Ames MM, Seibel NL, Reid JM, LiuMares W, Vezina LG, Ettinger AG, Reaman GH (1998) Phase I study of temozolomide in children and adolescent with recurrent solid tumors: a report from the Children's Cancer Group. J Clin Oncol 16:3037
15. O'Reilly SM, Newlands ES, Glaser MG, Brampton M, Rice-Edwards JM, Illingworth RD, Richards PG, Kennard C, Colquhoun IR, Lewis P, Stevens MFG (1993) Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumors. Eur J Cancer 29A:940
16. Panetta JC, Kirstein MN, Gajjar AJ, Nair G, Fouladi M, Heideman RL, Wilkinson M, Stewart CF (2002) Population pharmacokinetics of temozolomide and MTIC in infants and children with primary central nervous system tumors (abstract). Proc AACR 43:1355
17. Patel M, McCully C, Godwin K, Balis F (1995) Plasma and cerebrospinal fluid pharmacokinetics of temozolomide (abstract). Proc ASCO 14:1485
18. Riccardi R, Cefalo G, Ruggiero A, Abate ME, Massimino M, Zucchetti P, Mascarin M, Garrè ML, Spreafico F, Mastrangelo S, Clerico A, Ridola V, Mazzarella G, Di Rocco C, Donfrancesco A, Perilongo G, Fossati F, Madon E (2002) High response rate to temozolomide in heavily pretreated children with medulloblastoma (abstract). Proc AACR 43:3711
19. Shen F, Decosterd LA, Gander M, Leyvraz S, Biollaz S, Lejeune F (1995) Determination of temozolomide in human plasma and urine by high-performance liquid chromatography after solid-phase extraction. J Chromatogr B 667:291
20. 6-alkylguanine-DNA alkyltransferase. Clin Cancer Res 7:2309
21. Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, Baig G, Goddard C, Gibson NW, Slack JA, Newton C, Lunt E, Fizames C, Lavelle F (1987) Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl- imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 47:5846
22. Stupp R, Gander M, Leyvraz S, Newlands E (2001) Current and future developments in the use of temozolomide for the treatment of brain tumors. Lancet Oncol 2:552